Cargando…

Real-world single-center experience with direct-acting antivirals for improvement of the liver fibrosis after chronic hepatitis C treatment

BACKGROUND: Recently, new direct-acting antivirals (DAAs) are known to eradicate chronic hepatitis C (CHC) virus infection and prevent the progression of liver fibrosis. Liver fibrosis may predispose to liver cirrhosis or hepatocellular carcinoma. We investigated the effect of DAAs on liver fibrosis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Sun Hee, Shin, Hyun Phil, Lee, Joung Il
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683836/ https://www.ncbi.nlm.nih.gov/pubmed/33215505 http://dx.doi.org/10.1177/2040206620974835

Ejemplares similares

Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study
por: Kang, Yeo Wool, et al.
Publicado: (2021)

Direct-Acting Antiviral Treatment in Albanian Patients With Chronic Hepatitis C and Advanced Liver Fibrosis
por: Cuko, Liri, et al.
Publicado: (2022)

Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders
por: Dybowska, Dorota, et al.
Publicado: (2023)

Recurrent hepatitis C treatment with direct acting antivirals – a real life study at a Brazilian liver transplant center
por: Zanaga, L.P., et al.
Publicado: (2019)

Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease
por: Chang, Christine Y., et al.
Publicado: (2017)

Real-world single-center experience with entecavir and tenofovir disoproxil fumarate in treatment-naïve and experienced patients with chronic hepatitis B
por: Kim, Young Min, et al.
Publicado: (2018)

M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals
por: Saleh, Shereen A, et al.
Publicado: (2020)

Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan
por: Chang, Kao-Chi, et al.
Publicado: (2021)

Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV
por: Patel, Sonia Vibhakar, et al.
Publicado: (2020)

Evaluation of fibrosis in chronic hepatitis C patients treated with direct-acting antivirals
por: Tufan, Ayse Gokcen, et al.
Publicado: (2020)

The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals
por: Lee, Yu-Chi, et al.
Publicado: (2019)

Outcomes in Hepatitis C Positive Liver Transplantation: Timing of Direct-Acting Antiviral Treatment and Impact on Graft Fibrosis
por: Wellington, Jennifer, et al.
Publicado: (2021)

Real-World Drug Costs of Treating Hepatitis C Genotypes 1-4 with Direct-Acting Antivirals: Initiating Treatment at Fibrosis 0-2 and 3-4
por: Bach, Timothy A., et al.
Publicado: (2016)

Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections
por: Sun, Hsin-Yun, et al.
Publicado: (2022)

Pan-Genotypic Direct-Acting Antiviral Agents for Undetermined or Mixed-Genotype Hepatitis C Infection: A Real-World Multi-Center Effectiveness Analysis
por: Yen, Hsu-Heng, et al.
Publicado: (2022)

Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced
por: Lee, Hyun Woong, et al.
Publicado: (2017)

Direct-acting antiviral treatment for chronic hepatitis C in people who use drugs in a real-world setting
por: Koustenis, Kanellos Rafail, et al.
Publicado: (2020)

Real-world efficacy and safety of direct-acting antiviral drugs in patients with chronic hepatitis C and inherited blood disorders
por: Ruiz, Isaac, et al.
Publicado: (2021)

Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study
por: Kieran, Jennifer Ann, et al.
Publicado: (2015)

Sustained Virologic Response with Direct Acting Antivirals in HIV Coinfected Hepatitis C Patients and Its Effect on Liver Fibrosis
por: Lebron, Dora, et al.
Publicado: (2017)

Hepatic fibrosis changes in patients with chronic hepatitis C infection who respond to direct-acting antivirals
por: Alswat, Khalid, et al.
Publicado: (2022)

Regression in hepatic fibrosis in elderly Chinese patients with hepatitis C receiving direct-acting antiviral treatment
por: Niu, Bin, et al.
Publicado: (2023)

Efficacy and Safety of Direct-Acting Antiviral Therapy in Patients With Chronic Hepatitis C Virus Infection: A Real-World Single-Center Experience in Tianjin, China
por: Xia, Huan, et al.
Publicado: (2020)

Real-world observational experience with direct-acting antivirals for hepatitis C: baseline resistance, efficacy, and need for long-term surveillance
por: Loo, Nicole, et al.
Publicado: (2019)

Efficacy and safety of combined directly acting antivirals for treatment of Chinese chronic hepatitis C patients in a real-world setting
por: Chen, Jian-Hong, et al.
Publicado: (2017)

Real-world treatment outcome of direct-acting antivirals and patient survival rates in chronic hepatitis C virus infection in Eritrea
por: Ghebremeskel, Ghirmay Ghebrekidan, et al.
Publicado: (2023)

Factors associated with treatment failure of direct‐acting antivirals for chronic hepatitis C: A real‐world nationwide hepatitis C virus registry programme in Taiwan
por: Chen, Chi‐Yi, et al.
Publicado: (2021)

Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C
por: Ponziani, Francesca Romana, et al.
Publicado: (2017)

Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis
por: Toshikuni, Nobuyuki
Publicado: (2017)

The Risk of Hepatocellular Carcinoma After Directly Acting Antivirals for Hepatitis C Virus Treatment in Liver Transplanted Patients: Is It Real?
por: Strazzulla, Alessio, et al.
Publicado: (2016)

The Utility of Retinol-Binding Protein 4 in Predicting Liver Fibrosis in Chronic Hepatitis C Patients in Response to Direct-Acting Antivirals
por: Fayed, Hanan Mahmoud, et al.
Publicado: (2020)

Enhanced liver fibrosis score as a noninvasive biomarker in hepatitis C virus patients after direct-acting antiviral agents
por: Cossiga, Valentina, et al.
Publicado: (2022)

Direct-Acting Antiviral Therapy and Risk of Hepatocellular Carcinoma Recurrence in Patients with Chronic Hepatitis C
por: Lee, Chang Hun, et al.
Publicado: (2021)

A real-life study on the impact of direct-acting antivirals in the treatment of chronic hepatitis C in liver transplant recipients at two university centers in Northeastern Brazil
por: Silva, Isabella Patrícia Lima, et al.
Publicado: (2021)

Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease
por: Ryu, Ji Eun, et al.
Publicado: (2022)

Association Between Vitamin D Levels and Treatment Response to Direct-Acting Antivirals in Chronic Hepatitis C: A Real-World Study
por: Gayam, Vijay, et al.
Publicado: (2018)

Systematic review and meta-analysis: real-world effectiveness of direct-acting antiviral therapies in chronic hepatitis C genotype 3 in Asia
por: Wei, Bin, et al.
Publicado: (2018)

Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study
por: Sundberg, Isak, et al.
Publicado: (2018)

High Effectiveness of Broad Access Direct‐Acting Antiviral Therapy for Hepatitis C in an Australian Real‐World Cohort: The REACH‐C Study
por: Yee, Jasmine, et al.
Publicado: (2021)

Real-World Effectiveness and Safety of Direct-Acting Antivirals in Patients with Chronic Hepatitis C and Epilepsy: An Epi-Ter-2 Study in Poland
por: Pazgan-Simon, Monika, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jguqkcscr3qioccotd6npvf7ja